U.K.-based healthcare technology company Huma has announced that it secured over $80 million in a Series D funding round, increasing its total raised capital to more than $300 million. Key investors in this round included major players such as AstraZeneca, Leaps by Bayer, Hat Technology Fund 4 by HAT SGR, and HV Fund by Hitachi Ventures. The company also revealed the launch of its Huma Cloud Platform, a no-code solution designed to enhance the creation and integration of disease-management tools.
The Huma Cloud Platform is a versatile, cloud-agnostic framework that allows developers to build disease-management tools using pre-built modules and device-connectivity capabilities. It offers APIs and integration options, and can host and deploy predictive and diagnostic AI algorithms. This new product is aimed at transforming digital health solutions by enabling healthcare providers to integrate patient data from various sources, including hospital databases, mobile devices, and wearables, into cohesive and actionable insights.
Dr. Juergen Eckhardt, EVP and head of Leaps by Bayer, highlighted Huma's remarkable progress and growth, noting that their next-generation AI capabilities and the Huma Cloud platform can significantly enhance digital health solutions for patients. With this new funding, Huma aims to partner with pharmaceutical companies to deliver efficient, predictive, and proactive care. This significant investment underscores the growing importance of digital health technologies in improving patient outcomes and streamlining healthcare delivery.
Click here to read the original news story.